D.L. Carlson Investment Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.98M Buy
15,532
+1,230
+9% +$154K 0.34% 74
2025
Q4
$1.74M Buy
+14,302
New +$1.64M 0.29% 76
2023
Q4
Sell
-94,810
Closed -$6.92M 158
2023
Q3
$6.92M Sell
94,810
-8,888
-9% -$710K 1.4% 20
2023
Q2
$8.63M Buy
103,698
+153
+0.1% +$12.8K 1.65% 13
2023
Q1
$7.89M Buy
103,545
+17,826
+21% +$1.48M 1.79% 10
2022
Q4
$7.12M Buy
85,719
+2,387
+3% +$193K 1.53% 20
2022
Q3
$6.61M Buy
83,332
+19,536
+31% +$1.65M 1.44% 17
2022
Q2
$4.74M Buy
63,796
+19,685
+45% +$1.48M 1% 37
2022
Q1
$3.96M Buy
44,111
+156
+0.4% +$14.4K 0.66% 58
2021
Q4
$4.92M Buy
43,955
+7,054
+19% +$851K 0.79% 49
2021
Q3
$4.64M Buy
36,901
+55
+0.1% +$7.08K 0.81% 45
2021
Q2
$4.99M Buy
36,846
+129
+0.4% +$17K 0.86% 47
2021
Q1
$4.98M Sell
36,717
-39,882
-52% -$5.97M 0.91% 47
2020
Q4
$10.8M Buy
76,599
+3,469
+5% +$444K 1.96% 11
2020
Q3
$8.15M Buy
73,130
+19,137
+35% +$2.15M 1.72% 17
2020
Q2
$6.04M Buy
53,993
+2,740
+5% +$270K 1.8% 13
2020
Q1
$3.97M Buy
51,253
+4,438
+9% +$393K 1.5% 17
2019
Q4
$4.45M Buy
46,815
+943
+2% +$81.6K 1.29% 26
2019
Q3
$3.5M Sell
45,872
-60
-0.1% -$4.99K 1.1% 34
2019
Q2
$4.03M Sell
45,932
-5,145
-10% -$439K 1.24% 28
2019
Q1
$4.63M Buy
51,077
+29,147
+133% +$2.48M 1.35% 23
2018
Q4
$1.57M Sell
21,930
-19,465
-47% -$1.57M 0.52% 73
2018
Q3
$3.97M Buy
+41,395
New +$4.01M 1.12% 36

Other funds holding XBI

D.L. Carlson Investment Group's XBI Position: Q1 2026 in Review

D.L. Carlson Investment Group increased its State Street SPDR S&P Biotech ETF (XBI) stake by 8.6% in Q1 2026, buying an estimated $154K and bringing the position to 15,532 shares worth $1.98M. The position accounts for 0.34% of the portfolio, ranked #74.

D.L. Carlson Investment Group first reported a position in XBI in Q3 2018 and has held it in 23 quarters since. The position peaked at $10.8M in Q4 2020. 815 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • D.L. Carlson Investment Group held 15,532 shares of State Street SPDR S&P Biotech ETF worth $1.98M as of Q1 2026.
  • D.L. Carlson Investment Group bought 1,230 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $154K.
  • State Street SPDR S&P Biotech ETF made up 0.34% of D.L. Carlson Investment Group's portfolio in Q1 2026, its #74 holding.
  • D.L. Carlson Investment Group first reported a position in State Street SPDR S&P Biotech ETF in Q3 2018 and has held it in 23 quarters since.
  • D.L. Carlson Investment Group's State Street SPDR S&P Biotech ETF position peaked at $10.8M in Q4 2020.
  • 815 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on D.L. Carlson Investment Group's 13F filing for Q1 2026, filed 13 May 2026.